Skip to Content
Merck
CN

Key Documents

View All Documentation

189291

Atorvastatin, Calcium Salt - CAS 134523-03-8 - Calbiochem

A cell-permeable ring-opened pentasubstituted pyrrolyl-dihydroxyheptanoate compound that acts as a highly potent and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (IC50 = 7.5 nM in rat liver microsomes).

Synonym(s):

Atorvastatin, Calcium Salt - CAS 134523-03-8 - Calbiochem, (3 R,5 R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate, hemicalcium salt,, (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate, hemicalcium salt,

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Linear Formula:
[(C33H34FN2O5)2Ca · 3H2O]1/2
CAS Number:
134523-03-8
UNSPSC Code:
12352200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥97% (HPLC)

form

powder

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, desiccated (hygroscopic), protect from light

color

white

solubility

methanol: 10 mg/mL, clear, colorless, DMSO: 100 mg/mL, clear, colorless, ethanol: 2 mg/mL, clear, colorless, water: insoluble

shipped in

ambient

storage temp.

2-8°C

InChI

1S/2C33H35FN2O5.Ca/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);/q;;+2/p-2/t2*26-,27-;/m11./s1

InChI key

FQCKMBLVYCEXJB-MNSAWQCASA-L

General description

A cell-permeable ring-opened pentasubstituted pyrrolyl-dihydroxyheptanoate compound that acts as a highly potent and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (IC50 = 7.5 nM in rat liver microsomes). Reduces cholesterol synthesis and increases the expression LDL receptors in hepatocytes. Exhibits anti-inflammatory and anti-oxidant properties. Acts as a hypotensive agent that acts by enhancing flow mediated dilation. Shown to overcome carboplatin resistance in non-small-cell lung carcinomas possibly by suppressing Akt activity and upregulating TIMP-1.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Chen, J., et al. 2012. Int. J. Biochem. Cell Biol., in press.
Tycinska, A.M., et al. 2011. Arch. Med. Sci.7, 955.
Law, M.R., et al. 2003. BMJ326, 1423.

Youssef, S., et al. 2002. Nature420, 78.
Burnett, J.R., et al. 1998. Arterioscler. Thromb. Vasc. Biol.18, 1906.

Bustos, C., et al. 1998. J. Am. Coll. Cardiol.32, 2057.
Bocan, T.M.A., et al. 1992. Biochimica et Biophysica Acta1123, 133.
Roth, B.D., et al. 1991. J. Med. Chem.34, 463.
Shaw, M.K., et al. 1990. Biochem. Biophys. Res. Commun.170, 726.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class

10-13 - German Storage Class 10 to 13

Regulatory Information

监管及禁止进口产品

This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Peixiang Zhang et al.
Nature communications, 15(1), 5571-5571 (2024-07-03)
Statin drugs lower blood cholesterol levels for cardiovascular disease prevention. Women are more likely than men to experience adverse statin effects, particularly new-onset diabetes (NOD) and muscle weakness. Here we find that impaired glucose homeostasis and muscle weakness in statin-treated
G E Callera et al.
Methods in molecular biology (Clifton, N.J.), 1527, 251-269 (2017-01-25)
This chapter outlines protocols to evaluate protein localization, recruitment or phosphorylation levels in cholesterol/sphingolipids-enriched cell membrane domains and recommends experimental designs with pharmacological tolls to evaluate potential cell functions associated with these domains. We emphasize the need for the combination